Evelo Biosciences (NASDAQ:EVLO) major shareholder Ventures Fund Iv Gene Flagship acquired 281,250 shares of the firm’s stock in a transaction dated Friday, May 11th. The shares were bought at an average cost of $16.00 per share, with a total value of $4,500,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Evelo Biosciences opened at $16.00 on Friday, according to Marketbeat Ratings. Evelo Biosciences has a twelve month low of $16.00 and a twelve month high of $16.14.
Evelo Biosciences Company Profile
There is no company description available for Evelo Biosciences Inc
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.